A phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, single-dose and parallel-group study to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (Ova-Treg)) in patients with active refractory Crohn's Disease (Crohn's And Treg Study: CATS29)

Trial Profile

A phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, single-dose and parallel-group study to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (Ova-Treg)) in patients with active refractory Crohn's Disease (Crohn's And Treg Study: CATS29)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Regulatory T lymphocyte cell therapy-OvaSave (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms CATS29
  • Sponsors TxCell
  • Most Recent Events

    • 24 Nov 2016 Status changed from suspended to discontinued.
    • 24 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.
    • 13 Nov 2016 This trial was prematurely ended in Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top